导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.99% | 1459/4773 |
| 近一周 | -2.66% | 2779/5462 |
| 近一月 | -5.23% | 3113/5421 |
| 近一季 | -9.30% | 3162/5209 |
| 近半年 | -6.71% | 3129/4920 |
| 近一年 | 8.23% | 1212/4366 |
| 近两年 | 76.03% | 863/2954 |
| 近三年 | 39.14% | 740/2253 |
| 成立以来 | 0.70% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.07% 1073/4961 |
19.90% 1268/5312 |
- - |
- - |
| 2025 | 32.79% 1157/4813 |
2.33% 1404/3635 |
1.95% 2000/4076 |
25.88% 1373/4524 |
1.11% 1527/4813 |
| 2024 | 7.10% 1693/3463 |
-2.74% 1422/2808 |
-5.40% 1713/3014 |
16.70% 1378/3129 |
-0.25% 1360/3463 |
| 2023 | -6.33% 829/2656 |
7.97% 507/2280 |
-4.27% 1112/2385 |
-4.84% 1237/2515 |
-4.77% 1169/2655 |
| 2022 | -18.67% 742/2207 |
-14.10% 905/1919 |
3.44% 1153/2016 |
-10.91% 464/2113 |
2.75% 847/2208 |
| 2021 | 17.20% 241/1822 |
-1.61% 524/1255 |
9.85% 518/1330 |
4.85% 315/1466 |
3.43% 435/1822 |
| 2020 | 23.73% 644/1250 |
-4.16% 340/1028 |
17.36% 376/1067 |
6.30% 856/1164 |
3.48% 912/1184 |
| 2019 | 27.68% 535/1092 |
32.69% 171/754 |
-10.16% 717/804 |
0.36% 524/850 |
6.71% 563/918 |
| 2018 | -32.04% 516/834 |
- - |
- - |
- - |
-12.66% 468/691 |
| 2017 | 0.87% 463/714 |
- - |
- - |
- - |
- - |
| 2016 | -16.45% 375/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华夏中证500ETF VS. 长安沪深300非周期A(740101) |